Medscape

Diagnosis and Treatment of Pemphigus

Pemphigus is an autoimmune bullous disease, in which autoantibodies react with the cell–cell adhesion structures, desmosomes, causing blisters and erosions on the oral mucosa and skin. Pemphigus is ...
MedPage Today

Rituximab Tops Mycophenolate Mofetil for Pemphigus Vulgaris

Significantly more patients with moderate-to-severe pemphigus sustained their complete remission with rituximab (Rituxan) than with mycophenolate mofetil (MMF), a randomized trial showed. At 1 year, ...
The American Journal of Managed Care

Trial Finds Rituximab Is Superior to Mycophenolate Mofetil in Treating Pemphigus Vulgaris

A phase 3 trial explored which treatment option for pemphigus vulgaris, a rare skin disease, resulted in better outcomes after 52 weeks. In patients with pemphigus vulgaris, rituximab was superior to ...
Healio

Patients with pemphigus vulgaris more likely to achieve sustained complete remission with Rituxan

Please provide your email address to receive an email when new articles are posted on . Rituxan met a primary endpoint and demonstrated it is superior to mycophenolate mofetil in adults with moderate ...
Nasdaq

FDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris

PHILADELPHIA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for ...
Medscape

Pandemic Dictates Reconsideration of Pemphigus Therapy

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The conventional treatment mainstays for pemphigus are problematic during the COVID-19 pandemic, ...
Business Wire

Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus Vulgaris | Business Wire

PHILADELPHIA--(BUSINESS WIRE)--Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B ...
Monthly Prescribing Reference

Novel Cell Therapy Gets Orphan Drug Status for Mucosal Pemphigus Vulgaris

Desmoglein 3 chimeric autoantibody receptor T cell therapy, is designed to selectively target the cause of mucosal pemphigus vulgaris. The Food and Drug Administration (FDA) has granted Orphan Drug ...
Science Daily

Dose of medication more likely to put patients with pemphigus into remission

Researchers compare a lymphoma-dose regimen of rituximab to a rheumatoid arthritis regimen for the treatment of pemphigus. Pemphigus, an autoimmune disease mediated by B cells and which causes painful ...
Business Wire

Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus Vulgaris

PHILADELPHIA--(BUSINESS WIRE)--Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B ...
Nasdaq

Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus Vulgaris

PHILADELPHIA--(BUSINESS WIRE)-- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B ...